JP2002503714A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002503714A5 JP2002503714A5 JP2000532383A JP2000532383A JP2002503714A5 JP 2002503714 A5 JP2002503714 A5 JP 2002503714A5 JP 2000532383 A JP2000532383 A JP 2000532383A JP 2000532383 A JP2000532383 A JP 2000532383A JP 2002503714 A5 JP2002503714 A5 JP 2002503714A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydroxy
- hydrogen
- alkanoyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 hydroxy, mercapto, amino Chemical group 0.000 description 98
- 229910052739 hydrogen Inorganic materials 0.000 description 94
- 239000001257 hydrogen Substances 0.000 description 94
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 description 66
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 65
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 63
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 55
- 108090000765 processed proteins & peptides Proteins 0.000 description 55
- 125000000217 alkyl group Chemical group 0.000 description 54
- 125000004423 acyloxy group Chemical group 0.000 description 50
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 46
- 150000001720 carbohydrates Chemical class 0.000 description 44
- 150000001875 compounds Chemical class 0.000 description 41
- 125000001072 heteroaryl group Chemical group 0.000 description 41
- 125000003118 aryl group Chemical group 0.000 description 38
- 150000001413 amino acids Chemical class 0.000 description 35
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 33
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 33
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 32
- 125000004104 aryloxy group Chemical group 0.000 description 29
- 125000005553 heteroaryloxy group Chemical group 0.000 description 29
- 229910052757 nitrogen Inorganic materials 0.000 description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 29
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 29
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 28
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 24
- 125000001475 halogen functional group Chemical group 0.000 description 24
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 21
- 150000003839 salts Chemical class 0.000 description 18
- 150000002431 hydrogen Chemical class 0.000 description 16
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 5
- 125000006351 ethylthiomethyl group Chemical group [H]C([H])([H])C([H])([H])SC([H])([H])* 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 4
- 125000004442 acylamino group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
- 0 *C(C1(CC1)C(P)=C(C1=C2P)C(P)=C2P)(C1=O)P Chemical compound *C(C1(CC1)C(P)=C(C1=C2P)C(P)=C2P)(C1=O)P 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- CPEONABTMRSIKA-UHFFFAOYSA-N 1,4$l^{2}-oxazinane Chemical compound C1COCC[N]1 CPEONABTMRSIKA-UHFFFAOYSA-N 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/026,633 | 1998-02-20 | ||
| US09/026,633 US6025328A (en) | 1998-02-20 | 1998-02-20 | Antitumor agents |
| PCT/US1999/003660 WO1999042429A1 (en) | 1998-02-20 | 1999-02-19 | Antitumor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002503714A JP2002503714A (ja) | 2002-02-05 |
| JP2002503714A5 true JP2002503714A5 (https=) | 2006-03-23 |
Family
ID=21832953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000532383A Pending JP2002503714A (ja) | 1998-02-20 | 1999-02-19 | 抗腫瘍剤 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US6025328A (https=) |
| EP (1) | EP1056704B1 (https=) |
| JP (1) | JP2002503714A (https=) |
| KR (1) | KR100712589B1 (https=) |
| AT (1) | ATE238981T1 (https=) |
| AU (1) | AU764375B2 (https=) |
| BR (1) | BR9908125A (https=) |
| CA (1) | CA2321149C (https=) |
| DE (1) | DE69907419T2 (https=) |
| DK (1) | DK1056704T3 (https=) |
| EA (1) | EA200000847A1 (https=) |
| EE (1) | EE04777B1 (https=) |
| ES (1) | ES2199551T3 (https=) |
| GE (1) | GEP20032953B (https=) |
| HU (1) | HUP0100927A3 (https=) |
| IL (2) | IL137964A0 (https=) |
| IS (1) | IS2387B (https=) |
| NO (1) | NO20004162L (https=) |
| NZ (1) | NZ506592A (https=) |
| PL (1) | PL193958B1 (https=) |
| PT (1) | PT1056704E (https=) |
| SK (1) | SK286240B6 (https=) |
| TR (1) | TR200002418T2 (https=) |
| WO (1) | WO1999042429A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5932553A (en) * | 1996-07-18 | 1999-08-03 | The Regents Of The University Of California | Illudin analogs useful as antitumor agents |
| US5723632A (en) | 1996-08-08 | 1998-03-03 | Mgi Pharma, Inc. | Total synthesis of antitumor acylfulvenes |
| US6025328A (en) | 1998-02-20 | 2000-02-15 | The Regents Of The University Of California | Antitumor agents |
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US7015247B2 (en) * | 2000-10-12 | 2006-03-21 | Alvin Guttag | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs |
| US6436916B1 (en) | 2000-10-12 | 2002-08-20 | Alvin Guttag | Ibuprofen-aspirin and hydroxymethylacylfulvene analogs |
| EP1374907A3 (en) * | 2002-06-24 | 2004-01-07 | Ghanem Elias c/o Institut Jules Bordet Ghanem | Drug transport and delivery system |
| EP1599484A2 (en) * | 2003-02-21 | 2005-11-30 | Chugai Seiyaku Kabushiki Kaisha | Process for the preparation of hexacyclic camptothecin derivatives |
| US8697679B2 (en) * | 2003-03-07 | 2014-04-15 | N.V. Nutricia | Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress |
| US7126303B2 (en) * | 2003-07-08 | 2006-10-24 | Board Of Regents Of The University Of Nebraska | Robot for surgical applications |
| US7718385B2 (en) * | 2003-10-17 | 2010-05-18 | The Johns Hopkins University | Bioactivation of alkylating agents for cancer treatment |
| WO2007019308A2 (en) * | 2005-08-03 | 2007-02-15 | The Regents Of The University Of California | Illudin analogs useful as anticancer agents |
| TW200744603A (en) * | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| CA2626330A1 (en) * | 2005-10-19 | 2007-04-26 | Chugai Seiyaku Kabushiki Kaisha | Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-solube prodrug |
| US10285955B2 (en) | 2014-04-10 | 2019-05-14 | Af Chemicals, Llc | Affinity medicant conjugate |
| US11135182B2 (en) | 2014-04-10 | 2021-10-05 | Af Chemicals, Llc | Affinity medicant conjugates |
| WO2015157578A2 (en) | 2014-04-10 | 2015-10-15 | Af Chemicals, Llc | Affinity medicant conjugates |
| EP4524569A3 (en) | 2018-12-11 | 2025-06-18 | AF Chemical LLC | Methods, compositions and devices for treating cancer with illudofulvenes |
| US11591295B2 (en) | 2019-11-25 | 2023-02-28 | Af Chemicals Llc | Affinity illudofulvene conjugates |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4612302A (en) | 1983-11-14 | 1986-09-16 | Brigham And Women's Hospital | Clinical use of somatostatin analogues |
| US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
| JPS62234040A (ja) * | 1986-04-02 | 1987-10-14 | Kyowa Hakko Kogyo Co Ltd | Ｄｃ１０４３物質 |
| US4853371A (en) | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5439936A (en) * | 1989-10-03 | 1995-08-08 | The Regents Of The University Of California | Method of treating certain tumors using illudin analogs |
| EP0565519B1 (en) * | 1989-10-03 | 1996-08-28 | The Regents Of The University Of California | Illudin analogs as anti-tumor agents |
| GB9017024D0 (en) * | 1990-08-03 | 1990-09-19 | Erba Carlo Spa | New linker for bioactive agents |
| DZ1773A1 (fr) | 1993-04-27 | 2002-02-17 | Smithkline Beecham Corp | Antagonistes de récepteurs d'endothéline. |
| US5708163A (en) | 1994-03-15 | 1998-01-13 | Sloan-Kettering Institute Of Cancer Research | Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof |
| US6303120B1 (en) | 1994-03-15 | 2001-10-16 | Memorial Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the lewis y epitope and uses thereof |
| US5932553A (en) * | 1996-07-18 | 1999-08-03 | The Regents Of The University Of California | Illudin analogs useful as antitumor agents |
| US5723632A (en) * | 1996-08-08 | 1998-03-03 | Mgi Pharma, Inc. | Total synthesis of antitumor acylfulvenes |
| US6025328A (en) * | 1998-02-20 | 2000-02-15 | The Regents Of The University Of California | Antitumor agents |
-
1998
- 1998-02-20 US US09/026,633 patent/US6025328A/en not_active Expired - Fee Related
-
1999
- 1999-02-19 WO PCT/US1999/003660 patent/WO1999042429A1/en not_active Ceased
- 1999-02-19 CA CA2321149A patent/CA2321149C/en not_active Expired - Fee Related
- 1999-02-19 JP JP2000532383A patent/JP2002503714A/ja active Pending
- 1999-02-19 ES ES99907161T patent/ES2199551T3/es not_active Expired - Lifetime
- 1999-02-19 AU AU26886/99A patent/AU764375B2/en not_active Ceased
- 1999-02-19 BR BR9908125-3A patent/BR9908125A/pt not_active Application Discontinuation
- 1999-02-19 IL IL13796499A patent/IL137964A0/xx active IP Right Grant
- 1999-02-19 KR KR1020007009146A patent/KR100712589B1/ko not_active Expired - Fee Related
- 1999-02-19 DE DE69907419T patent/DE69907419T2/de not_active Expired - Lifetime
- 1999-02-19 DK DK99907161T patent/DK1056704T3/da active
- 1999-02-19 HU HU0100927A patent/HUP0100927A3/hu unknown
- 1999-02-19 AT AT99907161T patent/ATE238981T1/de not_active IP Right Cessation
- 1999-02-19 EE EEP200000472A patent/EE04777B1/xx not_active IP Right Cessation
- 1999-02-19 EA EA200000847A patent/EA200000847A1/ru unknown
- 1999-02-19 SK SK1251-2000A patent/SK286240B6/sk not_active IP Right Cessation
- 1999-02-19 GE GEAP19995551A patent/GEP20032953B/en unknown
- 1999-02-19 TR TR2000/02418T patent/TR200002418T2/xx unknown
- 1999-02-19 EP EP99907161A patent/EP1056704B1/en not_active Expired - Lifetime
- 1999-02-19 PT PT99907161T patent/PT1056704E/pt unknown
- 1999-08-31 US US09/386,555 patent/US6323181B1/en not_active Expired - Lifetime
-
2000
- 2000-08-16 NZ NZ506592A patent/NZ506592A/en unknown
- 2000-08-16 PL PL99342614A patent/PL193958B1/pl not_active IP Right Cessation
- 2000-08-17 US US09/641,191 patent/US6548679B1/en not_active Expired - Lifetime
- 2000-08-18 IS IS5588A patent/IS2387B/is unknown
- 2000-08-18 NO NO20004162A patent/NO20004162L/no not_active Application Discontinuation
- 2000-08-20 IL IL137964A patent/IL137964A/en not_active IP Right Cessation
-
2001
- 2001-11-05 US US10/013,009 patent/US6855696B2/en not_active Expired - Lifetime
-
2003
- 2003-04-14 US US10/413,449 patent/US6908918B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002503714A5 (https=) | ||
| AU2007345952C1 (en) | Positively charged water-soluble prodrugs of 1H-imidazo[4, 5-c]quinolin-4-amines and related compounds with very high skin penetration rates | |
| US8501793B2 (en) | Blood flow promoters for cauda equina tissues | |
| EP0909560A3 (en) | Treatment o tumors with compounds having RXR retinoid receptor agoinst activity | |
| JP2002501049A5 (https=) | ||
| CA2321149A1 (en) | Antitumor agents | |
| EP1228061A1 (en) | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors | |
| RU2002135312A (ru) | Средство, усиливающие секрецию гормона роста | |
| JP2003531821A5 (https=) | ||
| EA021974B1 (ru) | Противовирусное соединение | |
| JP2002533472A5 (https=) | ||
| ES2971041T3 (es) | Terapia combinada de inhibidores del receptor 9 de quimiocina C-C (CCR9) y anticuerpos bloqueadores anti-integrina alfa4beta7 para el tratamiento de la enfermedad inflamatoria intestinal | |
| JP2021152063A5 (https=) | ||
| JP2001526218A5 (https=) | ||
| JP2002519425A5 (https=) | ||
| WO2014107730A2 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| JP2002515427A5 (https=) | ||
| RU2002100058A (ru) | Кристаллические производные 1-метилкарбапенема | |
| JP2002537258A5 (https=) | ||
| RU2002130247A (ru) | Производные оксадиазола, обладающие противоопухолевым действием | |
| JP2002509858A5 (https=) | ||
| US20070010458A1 (en) | Drugs for the arthritis treatment | |
| RU2003134629A (ru) | Соединения цефема | |
| JP2003520208A5 (https=) | ||
| RU2007131435A (ru) | Противоопухолевое средство |